Precision Medicine and Artificial Intelligence – The Perfect Fit for Autoimmunity
A new book ‘Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity‘ with Academic Press /Elsevier Science Publishing Co Inc; editor Michael Mahler was co-authored by IAG’s CEO Dr Olga Kubassova, and collaborators Dr. Faiq Shaikh and Dr. Michael Mahler, who contributed to the chapter ‘History, current status and future directions of Artificial Intelligence’.
Access Online: https://www.elsevier.com/
Published: 12 March 2021
Authors: Olga Kubassova, Faiq Shaikh, Carlos Melus, Marvin J. Fritzler, Brenden Rossin, Mary Ann Aure, Jan Trøst Jørgensen, Savino Sciascia, Marie Hudson, Joanne Bradbury, Minoru Satoh, Gary L. Norman, Nicola Bizzaro, Danilo Villalta, Diego Vergani, Giorgina Mieli-Vergani, Gideon M. Hirschfield, Kevin D. Deane, May Y. Choi, Lily W. Martin, Lauren C. Prisco, Laura Martinez-Prat, Michael Mahler, Jeffrey A. Sparks, Kim MacMartin-Moglia, et al.
Precision Medicine and Artificial Intelligence: The Perfect Fit for Autoimmunity covers background on artificial intelligence (AI), its link to precision medicine (PM), and examples of AI in healthcare, especially autoimmunity. The book highlights future perspectives and potential directions as AI has gained significant attention during the past decade. Autoimmune diseases are complex and heterogeneous conditions, but exciting new developments and implementation tactics surrounding automated systems have enabled the generation of large datasets, making autoimmunity an ideal target for AI and precision medicine.
More and more diagnostic products utilize AI, which is also starting to be supported by regulatory agencies such as the Food and Drug Administration (FDA). Knowledge generation by leveraging large datasets including demographic, environmental, clinical and biomarker data has the potential to not only impact the diagnosis of patients, but also disease prediction, prognosis and treatment options.
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.
Reach out to our expert team to discuss your development programs: email@example.com
- History, current status, and future directions of artificial intelligence
Olga Kubassova, Faiq Shaikh, Carlos Melus, and Michael Mahler
- Precision medicine as an approach to autoimmune diseases
Marvin J. Fritzler and Michael Mahler
- Biomarker and data science as integral part of precision medicine
Carlos Melus, Brenden Rossin, Mary Ann Aure, and Michael Mahler
- Companion and complementary diagnostics: A key to precision medicine
Jan Trøst Jørgensen
- Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine
Savino Sciascia, Marie Hudson, Marvin J. Fritzler, Minoru Satoh, and Michael Mahler
- The evolving potential of precision medicine in the management of autoimmune liver disease
Gary L. Norman, Nicola Bizzaro, Danilo Villalta, Diego Vergani, Giorgina Mieli-Vergani, Gideon M. Hirschfield, and Michael Mahler
- Precision medicine in autoimmune disease
Kevin D. Deane
- Development of multi-omics approach in autoimmune diseases
May Y. Choi, Marvin J. Fritzler, and Michael Mahler
- N-of-1 trials: Implications for clinical practice and personalized clinical trials
Joanne Bradbury and Michael Mahler
- Health risk assessment and family history: Toward disease prevention
Lily W. Martin, Lauren C. Prisco, Laura Martinez-Prat, Michael Mahler, and Jeffrey A. Sparks
- Regulatory aspects of artificial intelligence and machine learning-enabled software as medical devices (SaMD)
Michael Mahler, Carolina Auza, Roger Albesa, Carlos Melus, and Jungen Andrew Wu
- Precision medicine from the patient’s perspective: More opportunities and increasing responsibilities
Kim MacMartin-Moglia and Michael Mahler